Physician profile
Lois Schertz
NPI 1306300314
$5,773.17
in general payments reported to CMS, 2019-2025
20 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $611 · 2022: $531 · 2023: $902 · 2024: $1,705 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,630.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,193.45 | 2021-2025 | |
| Novo Nordisk INC | $1,149.92 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $939.93 | 2021-2025 | Injectafer |
| Dexcom, INC. | $686.66 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Lilly USA, LLC | $473.81 | 2023-2025 | Zepbound, Mounjaro |
| Astellas Pharma US INC | $305.09 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $259.12 | 2023-2025 | |
| Genzyme Corporation | $259.03 | 2025 | |
| Cequr Corporation | $129.13 | 2025 | Cequr Simplicity |
| Gilead Sciences, INC. | $95.25 | 2021 | |
| Abbott Laboratories | $79.23 | 2023-2024 | Freestyle Libre 3 |
| Sage Therapeutics, LLC | $36.03 | 2024 | |
| Glaxosmithkline, LLC. | $29.69 | 2021 | |
| Genentech USA, INC. | $24.04 | 2025 | Xofluza |
| Invivyd INC | $23.03 | 2025 | Pemgarda |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $21.25 | 2025 | Qelbree |
| Novartis Pharmaceuticals Corporation | $17.79 | 2025 | |
| Cosette Pharmaceuticals INC. | $17.56 | 2025 | Vyleesi |
| Kaleo, INC. | $16.63 | 2022 | |
| Lundbeck LLC | $16.53 | 2025 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lois Schertz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.